Prevention – Passive smoking and pregnancy

Tim S. Nawrot, Bianca Cox, Bram G. Janssen, Michelle Plusquin

Centre for Environmental Sciences, Hasselt University, Belgium
Leuven University, Department of Public Health & Primary Care, Belgium

1. Introduction

Epidemiological studies have demonstrated that tobacco smoke is a major cause of both cancer and vascular diseases. More than 3800 chemicals are present in tobacco smoke, which may cause oxidative stress via biotransformation or by macrophage activation. In 1954, Richard Doll and Bradford Hill published the first prospective evidence on cigarette smoking and lung cancer [1,2]. In 1962, Framingham investigators published data showing that smoking increased the risk of heart disease [3]. Nevertheless, despite the strong evidence, uncertainty was manufactured and enlarged. This strategy is a common practice to reduce the public health implications from epidemiological findings and was used not only by tobacco companies but also by other industrial arms, including asbestos and lead factories [4]. For almost half a century, the tobacco companies hired scientists to dispute first that smokers were at greater risk of dying of lung cancer; second, the role of tobacco use in heart disease; and finally, the evidence that environmental tobacco smoke increased disease risk in non-smokers [5,6].

The effect of in-utero exposures on health in childhood and later in life is a growing area of research interest, with major public health implications. Children are vulnerable to the adverse effects of environmental tobacco smoke as their lungs and immune system are undergoing further development. The first publications of detrimental health effects of parental smoking on children’s respiratory health were published in the early 1970s [7]. Exposure to environmental tobacco smoke in the first 2 years of life has been estimated in some European countries by Pattenden et al. [8] and ranged from 19% in Germany to 70% in Bulgaria.

2. Meta-analytical evidence of early-life effects

There is pooled evidence that constituents of cigarette smoke cross the placenta, induce pregnancy complications, reduce intrauterine foetal growth and increase the risk of preterm delivery (Table 1) [9,10]. Meta-analytical evidence has also shown increased risk of respiratory and ear infections [11–13], overweight [14] and an increase in blood pressure [15] in early life and/or childhood, suggesting that maternal smoking in pregnancy influences the foetal development of different organ systems. Indeed, low birth weight and preterm delivery are also determinants of health risks later in life, including childhood asthma [16,17]. A cross-sectional study of 11,500 participants of 8–11-year-old children showed that prenatal exposure to cigarette smoke has a stronger effect on childhood asthma compared with postnatal smoke [18]. Prenatal exposure to maternal smoking without subsequent postnatal exposure to environmental tobacco smoke was related to the presence of asthma at school age with an odds ratio (OR) of 1.8 (95%CI: 1.1–2.9) [18].

Parental smoking increases the risk of acute lower respiratory tract diseases in children [12,13]. The pooled estimates showed a higher risk in association with smoking by the mother (OR: 1.56, 95%CI: 1.51–1.62) than with smoking by the father (OR: 1.31, 95%CI: 1.20–1.42) [12]. The higher risk related to the mother’s smoking could be explained by the fact that young children usually spend more time with their mother or by the interplay with maternal smoking during pregnancy. In addition to lower respiratory tract infections (OR: 1.51 95%CI: 1.44–1.52), exposure to environmental tobacco smoke has been associated with an increased risk of otitis media (OR: 1.32, 95%CI: 1.14–1.52) [12].

Exposure to prenatal tobacco increases the level of genetic damage in newborns and children. A meta-analysis performed in children exposed to environmental tobacco smoke showed that children and newborns had, respectively, 1.3 and 6.7 times higher levels of haemoglobin adducts compared with non-exposed newborns [19]. Available meta-analytical evidence of an association between in-utero exposure to tobacco smoke from the parents and childhood cancer seems weak. Maternal smoking was estimated as an increased risk
<table>
<thead>
<tr>
<th>Disease</th>
<th>Author/Year (population)</th>
<th>Design</th>
<th>N articles</th>
<th>N</th>
<th>Pooled Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placenta previa</td>
<td>Castles et al. [9] (North America, Western Europe)</td>
<td>Case–control Cohort</td>
<td>6</td>
<td>50.695 Patients</td>
<td>1.58 (1.04–2.12)</td>
</tr>
<tr>
<td>Abruptio placenta</td>
<td></td>
<td></td>
<td>8</td>
<td>57.302</td>
<td>1.62 (1.46–1.77)</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td></td>
<td></td>
<td>9</td>
<td>10.632</td>
<td>1.77 (1.31–2.22)</td>
</tr>
<tr>
<td>Preterm PROM</td>
<td></td>
<td></td>
<td>6</td>
<td>34.668</td>
<td>1.7 (1.18–2.25)</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td></td>
<td></td>
<td>5</td>
<td>4.451</td>
<td>0.51 (0.38–0.64)</td>
</tr>
<tr>
<td>Preterm delivery (&lt;32 weeks but &lt;37 weeks of gestation)</td>
<td>Shah et al. [10] (Europe, North America)</td>
<td>Case–control</td>
<td>20</td>
<td>Cases: &gt;100.000</td>
<td>1.27 (1.21–1.33)</td>
</tr>
<tr>
<td>Acute lymphoblastic Leukaemia (Childhood)</td>
<td>Boffeta et al. [20] (Europe, North America)</td>
<td>Case–control</td>
<td>4</td>
<td>Primary Not Given</td>
<td>Paternal smoking during pregnancy 1.17 (0.96–1.42)</td>
</tr>
<tr>
<td></td>
<td>Milne et al. [23] (Europe, North America, Australia)</td>
<td>Case–control</td>
<td>11</td>
<td>Cases: 1994</td>
<td>Paternal smoking around the time of conception 1.15 (1.06–1.24)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>3</td>
<td>Primary Not Given</td>
<td>Smoking by Either Parent 0.99 (0.70–1.40)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>31</td>
<td>Primary Not Given</td>
<td>Asthma Smoking by Either Parent: 1.23 (1.14–1.33)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>9</td>
<td>16.690 Participants</td>
<td>Maternal Smoking During Pregnancy Systolic Blood Pressure 0.67 mmHg (0.31 to 1.04)</td>
</tr>
<tr>
<td></td>
<td>Marian et al. [52] (Asia, Europe, North America)</td>
<td>Case–control</td>
<td>25</td>
<td>~220.000 Participants</td>
<td>Childhood Exposure: 0.98 (0.88–1.08)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>12</td>
<td>900 participants 6351 cases 6253 controls Primary not given</td>
<td>Maternal smoking during pregnancy 1.10 (1.03–1.19)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>39</td>
<td></td>
<td>Cough Smoking by either parent: 1.35 (1.27–1.43)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>12</td>
<td>Primary not given</td>
<td>Maternal smoking during the pregnancy 1.04 (0.92–1.18)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>10</td>
<td>1627 cases 2974 controls Primary not given</td>
<td>Paternal smoking during pregnancy 1.22 (1.05–1.40)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>5</td>
<td></td>
<td>HB adducts Children exposed to environmental tobacco smoke: 1.38 (0.98–1.96)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>5</td>
<td></td>
<td>Prenatal Exposure: 6.67 (2.56–17.24)</td>
</tr>
<tr>
<td></td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case–control</td>
<td>5</td>
<td></td>
<td>SCEprenatal exposure: 1.02 (0.94–1.10)</td>
</tr>
<tr>
<td>Condition</td>
<td>StudySource</td>
<td>StudyDesign</td>
<td>N</td>
<td>Primary Analysis</td>
<td>Odds Ratio</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----</td>
<td>-----------------</td>
<td>------------</td>
</tr>
<tr>
<td>Lower respiratory illnesses</td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case-control Cohort</td>
<td>38</td>
<td>Primary not given</td>
<td>1.51 (1.44–1.59)</td>
</tr>
<tr>
<td>Lower respiratory tract infection</td>
<td>Li et al. [11] (Asia, Europe, North America)</td>
<td>Case-control Cohort</td>
<td>13</td>
<td>32,945 cases</td>
<td>Maternal smoking: 1.93 (1.66–2.25)</td>
</tr>
<tr>
<td>Lymphatic and haematopoietic Neoplasm (childhood)</td>
<td>Boffeta et al. [20] (Europe, North America)</td>
<td>Case-control</td>
<td>9</td>
<td>Cases: 3610 Controls: 5054</td>
<td>Maternal smoking during pregnancy 0.95 (0.76–1.19)</td>
</tr>
<tr>
<td>Kidney cancer (childhood)</td>
<td>Boffeta et al. [20] (Europe, North America)</td>
<td>Case-control</td>
<td>5</td>
<td>Cases: 442 Controls: 2536</td>
<td>Maternal smoking during pregnancy 1.50 (1.36–1.65)</td>
</tr>
<tr>
<td>Middle ear effusion</td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Cohort</td>
<td>9</td>
<td>Primary not given</td>
<td>Maternal smoking during pregnancy 1.49 (1.13–1.96)</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma (childhood)</td>
<td>Oken et al. [32] (Australia, Europe, North America)</td>
<td>Cohort</td>
<td>14</td>
<td>84,563 Participants</td>
<td>Paternal smoking: 0.90 (0.70–1.15)</td>
</tr>
<tr>
<td>Overweight</td>
<td>Boffeta et al. [20] (Europe, North America)</td>
<td>Case-control Cohort</td>
<td>4</td>
<td>Primary not given</td>
<td>Maternal smoking during pregnancy 1.50 (1.36–1.65)</td>
</tr>
<tr>
<td>Recurrent otitis media</td>
<td>Oken et al. [32] (Australia, Europe, North America)</td>
<td>Case-control Cohort</td>
<td>14</td>
<td>84,563 Participants</td>
<td>Paternal smoking: 1.32 (1.14–1.52)</td>
</tr>
<tr>
<td>Respiratory tract infections</td>
<td>Peat et al. [13] (Asia, Australia, Chili, Europe, New Zealand, USA)</td>
<td>Case-control Cohort</td>
<td>14</td>
<td>Primary not given</td>
<td>Maternal smoking during pregnancy 1.50 (1.36–1.65)</td>
</tr>
<tr>
<td>Sudden infant death syndrome (after prone-sleep-position intervention programs)</td>
<td>Mitchell et al. [24] (Europe, New Zealand, US)</td>
<td>Case-control Cohort</td>
<td>24</td>
<td>Cases: 15,694 Controls: 3,592,021 Cases: 719 Controls: 4885</td>
<td>Maternal smoking, mother does not smoke 1.49 (1.25–1.77)</td>
</tr>
<tr>
<td>Wheeze</td>
<td>Moritsugu et al. [12] (Europe, North America, Australia, Asia, Africa)</td>
<td>Case-control Cohort</td>
<td>45</td>
<td>Primary not given</td>
<td>Maternal smoking: 1.28 (1.21–1.35)</td>
</tr>
</tbody>
</table>

* Odds ratio.

* Relative risk.

* PROM, premature rupture of membranes is a rupture (breaking open) of the membranes (amniotic sac) before labour begins. If PROM occurs before 37 weeks of pregnancy, it is called preterm premature rupture of membranes (PPROM).

* MR is a point estimate of the relative effect of the exposure on biomarker level detected in each study taking the value 1 when there is no effect, values >1 when exposure is associated with a decreased level of the investigated biomarker.

* SCE: sister chromatid exchange is the exchange of genetic material between two identical sister chromatids. The reason for the SCE is not known but it is required and used for mutagenic testing of many products. Four to five sister chromatid exchanges are in the normal distribution, 14–100 exchanges are not normal and present a danger to the organism.

* Primary analysis of overweight has been chosen, defined as BMI ≥85th percentile or ≥90th percentile for age and sex.
of 10% (95%CI: 1.03–1.19) for childhood cancer, yet no significant elevated risk was found for lymphomatic and haemato-
poietic neoplasm, or for cancer of the central nervous system or kidney cancer (Table 1) [20]. When considering maternal and paternal in-utero exposure to genotoxic compounds, a difference in the mode of action is implied in the direct trans-
placental effects versus the preconception alterations. Car-
cinogens in tobacco can induce DNA damage in sperm: male smokers have higher levels of 8-oxo-2-deoxyguanosine in their semen than non-smokers, which may result in oxida-
tive damage to sperm DNA [21,22]. Paternal smoking during conception and acute lymphoblastic leukaemia are related with a pooled odds of 1.15 (CI: 1.06–1.24), paternal exposure during pregnancy is not [20,23]. Furthermore, meta-analytical work suggests an increased risk after paternal exposure to to-
bacco smoke with childhood non-Hodgkin lymphoma and tu-
mors in the central nervous system [20].

Based on pooled evidence of 25 studies [24], maternal smoking was associated with almost a 4-fold time increase in risk of sudden infant death syndrome. The corresponding risk of paternal smoking with absence of maternal smoking was 1.49 (Table 1). While the effect of smoke exposure in utero seems to be stronger, postnatal environmental tobacco smoke has been found to increase the risk of sudden infant death syndrome even after controlling for prenatal exposure. How-
ever, in most cases this is difficult to distinguish as most chil-
dren that have been exposed in utero are also exposed during their first months of life.

3. Smoking ban and health gains

The positive effect of smoking cessation suggests a causal asso-
ciation between active smoking and cardiovascular disease [25]. Evidence from observational studies shows a decrease in cardio-
vascular events in progression of atherosclerosis in those who quit smoking compared with those continuing to smoke ciga-
nettes. Along with this, evidence from cohort studies and ecolog-
cal evidence on recent smoking bans (introduced by law) consistsently shows a rapid decrease in hospitalisation for myo-
cardial infarction (MI). The pooled aggregated data showed that the rate of acute MI hospitalisation in countries that imple-
mented a smoking ban law, decreased 12 months after its imple-
mentation, on average by 17% (95%CI: 20–13%) [26]. The rapid decrease in MI after introduction of bans suggests an interplay between chronic and acute processes, including triggers. A trig-
ger can be defined as an external stimulus that produces acute physiological or pathophysiological changes. The idea of the pathophysiological relevance of triggers leading to the onset of acute myocardial infarction (MI) has been proposed [27]. In gen-
eral, ageing leads to functional and structural abnormalities of the arterial wall, which are amplified by hypertension and ath-
erosclerosis [28]. A vulnerable atherosclerotic plaque might lead to an occlusive thrombus which is more likely to be formed if other factors come into play to narrow homeostasis and in-
crease vasoconstriction. The role of triggers such as alcohol [29], anger [30,31], physical exertion [31,32] and use of marijuana [33] in the onset of MI is recognised [34].

Recently gained evidence supports the notion that prema-
ture birth is also a syndrome which might have trigger com-
ponents, including ambient temperature and smoking [35,36]. Recent Scottish [36] and Belgian [35] data support reductions in the rate of preterm births after the implementa-
tion of smoking bans, whereas no such decrease was evident in the years or months before these bans.

In Belgium, smoke-free legislation was implemented in dif-
ferent phases (in public workplaces and most workplaces in January 2006, in restaurants January 2007, and in bars serving food January 2010). We were able to demonstrate a consistent pattern of changes in preterm delivery with stepwise reductions over the different enforcements. In an analysis using a birth register comprising 606,877 live-births, we observed an immediate change in the risk of spontaneous preterm delivery of –3.13% (95%CI: –4.37% to –1.87%; P < 0.01) on 1st January 2007 (ban on smoking in restaurants), and an annual slope change of –2.65% (–5.11% to –0.13%; P = 0.04) after 1st January 2010 (ban on smoking in bars serving food). In 716,941 Scottish new-
borns, the risk was decreased by 11.72% (95% CI: –15.87 to –7.35) 3 months prior to the introduction of the comprehensive smok-
ing ban in 2006. Similarly to Belgian findings, a study on the im-
pact of the Irish workplace smoking ban on birth weight and preterm birth found a protective effect only on the latter out-
come [37]. Although their analysis was limited to a comparison of rates 1 year before and after the ban, they even found an in-
crease in the risk of low birth weight.

The smoking ban studies must be viewed as an investiga-
tion of the possible impact of a ‘population intervention’ rather than an investigation of changes in individual behav-
iour. It is possible that unmeasured confounders were respon-
sible for the observed changes. Nevertheless, it is hard to con-
ceive of a factor that could change the population risk of preterm births after the introduction of the different succes-
sive smoking bans. It is unlikely that our observations could be explained by abrupt changes in therapeutic strategies coin-
ciding with the smoking bans. Nevertheless, the Belgian study collected data on the prescription of atosiban and on cervical cerclage treatment from a social security organisation covering 42% of the population. Atosiban is an inhibitor of oxytocin and vasopressin and is specifically used to halt premature la-
bour. Cervical cerclage is used for the treatment of cervical incompetence, a condition where the cervix has opened slightly and there is a risk of miscarriage.

Given that even a mild reduction in gestational age has been linked to adverse health outcomes in early and later life, these population interventions have important public health implications. Indeed, a Swedish study found that, even among those born late preterm (34–36 weeks), preterm birth was associated with a 31% (13–50%) increase in mortality in young adulthood [38].

4. Molecular epidemiological aspects

The human placenta forms the interface between foetal and maternal circulation, and by controlling nutrient supply plays a critical role in the regulation of foetal growth and develop-
ment. Maternal smoking causes perturbations in this utero-
placental exchange as it increases the risk of low birth weight [39,40] and preterm delivery [35,41]. The mechanisms under-
lying these observed effects remain unclear, but emerging data suggest that biochemical, genetic and epigenetic activi-
ties respond to and are modified by in-utero tobacco exposure. Nutrients and potential pollutants are metabolised, making the placenta a molecular ‘footprint’ to which the foetus has been exposed in utero.

Mitochondria are abundant in placental cells, they provide energy for the functioning of this metabolically active organ. Each cell contains approximately 200–2000 mitochondria, carrying between two and ten copies of mitochondrial DNA (mtDNA). Recently, by assessing the relative mtDNA content (a marker of mitochondrial damage and dysfunction), its functioning has been linked to various disease mechanisms [42,43]. The placental mtDNA content has been shown to be very adaptive to environmental insults, including maternal smoking [44] and air pollution [45]. The relative mtDNA content is decreased by 37% (P < 0.02) in placentas of mothers who smoke [44] compared with a decrease of 17.4% (P = 0.05) for each 10-μg/m³ increase in PM10 exposure during the third trimester of pregnancy [45].

Important questions remain concerning how mitochondrial biogenesis and maintenance are regulated as a response to tobacco exposures, and how these relate to placental functioning. An attractive link between adverse insults and altered foetal development is gene regulation. Maternal smoking during pregnancy can lead to changes in placental gene expression levels, which is epigenetically regulated by DNA methylation, histone modifications or non-coding RNAs. Epigenetic changes can occur throughout the course of life as a result of environmental conditions. Much of the epigenome is already established in germ cells and embryos as it appears to be particularly important for the regulation of embryonic growth and placental development [46]. Recently, studies investigating cord blood and placental tissue showed that the epigenetic system is sensitive to tobacco exposure in utero. Global DNA methylation levels in cord blood is lower among newborns with smoking mothers (mean = 15.04%; 95%CI: 8.4–21.7) compared with second-hand smokers (21.1%; 95%CI: 16.6–25.5) and their non-smoking counterparts (mean = 29.2%; 95%CI: 20.1–38.1) [47]. An epigenome-wide methylation study in cord blood of newborns exposed to tobacco smoke during pregnancy showed that genes that play an important role in detoxifying components of tobacco smoke (AHR and CYP1A1) are differentially methylated [48]. Accordingly, Suter and colleagues reported site-specific changes in DNA methylation of the CYP1A1 promoter, and this hypomethylation correlated with an increase in CYP1A1 gene expression in the placenta [49]. They showed in an epigenome-wide methylation study on placental tissue that methylation levels of 623 genes are deregulated in a CpG site-specific manner [50].

Despite a limited number of (epi)genomic studies in cord blood and placental tissue, we are getting a better picture of how maternal tobacco smoke can alter placental functioning and contribute to adverse pregnancy outcomes. Therefore the potential health consequences of changes in mitochondrial functioning, gene expression and epigenetics in early life should be further elucidated.

Conflict of interest statement

None declared.

REFERENCES


